BSX Stock Recent News
BSX LATEST HEADLINES
Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective for LBBA pacing.
Boston Scientific (BSX) closed the most recent trading day at $82.52, moving -1.19% from the previous trading session.
MARLBOROUGH, Mass. , Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the indication for current-generation INGEVITY™+ Pacing Leads – thin wires placed inside the heart and connected to an implantable device – to include conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) when connected to a single- or dual-chamber pacemaker.
In the closing of the recent trading day, Boston Scientific (BSX) stood at $82.94, denoting a -0.14% change from the preceding trading day.
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Boston Scientific Corporation (NYSE:BSX ) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:00 AM ET Company Participants Brad Sutton - Chief Medical Officer, AF Solutions Jon Monson - SVP, IR Michael F. Mahoney - Chairman and CEO Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Lawrence Biegelsen Okay.
Medical device maker Boston Scientific Corporation (BSX) shares rising on product, financial performance.
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.